CiceroDx, Inc. is a diagnostics company dedicated to the advancement of clinical assays for understudied diseases.

Endometriosis is a major focus of CiceroDx, now offering for the first time a global test for all stages of endometriosis. This disease affects over 176 million women and takes 11 years on average to diagnose. Many women spend years dealing with pain, infertility and bowel or bladder symptoms without knowing that endometriosis is the cause.

The employees of CiceroDx are advocates for women and strive to provide advances in this field. In addition to our current test on endometrial biopsies, we are currently validating multiple methodologies leading towards potential blood and urine tests for this disease. Our research team also continues to work in concert with those efforts by investigating and developing improved pathways to treat endometriosis.

The company is headed by its CEO and President, Christopher Jackson. With headquarters in Southern California, Mr. Jackson leads a team of patient focused employees available to help both healthcare professionals and their patients better understand how these new testing modalities can impact treatments and long term outcomes.

The laboratory for our Beta 3 and BCL6 testing (ReceptivaDxTM), located in Greenville, SC, is supervised by Dr. David P. Schammel, a well-known and respected gynecologic pathologist, and Vice Chair of Pathology Associates.

Our scientific advisor is Bruce A. Lessey MD, PhD, who co-discovered both beta 3 integrin and BCL6 biomarkers as diagnostic tests for endometriosis. Along with his colleague at University of North Carolina, Steven L. Young MD, PhD, this ground breaking scientific breakthrough is providing answers to women with unexplained infertility and pelvic pain throughout the US and around the world.
Subscribe to our newsletter and stay up to date with ReceptivaDx.
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
© 2017 Receptivadx. All Rights Reserved